Selvi Durmuş

1.2k total citations
24 papers, 1.0k citations indexed

About

Selvi Durmuş is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Selvi Durmuş has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Selvi Durmuş's work include Drug Transport and Resistance Mechanisms (12 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Melanoma and MAPK Pathways (3 papers). Selvi Durmuş is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Melanoma and MAPK Pathways (3 papers). Selvi Durmuş collaborates with scholars based in Netherlands, Türkiye and Japan. Selvi Durmuş's co-authors include Alfred H. Schinkel, Els Wagenaar, Jos H. Beijnen, Rolf W. Sparidans, Izabella Ślęzak-Prochazka, Bart‐Jan Kroesen, Anke van den Berg, Jeroen J. M. A. Hendrikx, Anita van Esch and Jan H.M. Schellens and has published in prestigious journals such as Cancer Research, Oncogene and Clinical Cancer Research.

In The Last Decade

Selvi Durmuş

24 papers receiving 1.0k citations

Peers

Countries citing papers authored by Selvi Durmuş

Since Specialization

Citations

This map shows the geographic impact of Selvi Durmuş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Selvi Durmuş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Selvi Durmuş more than expected).

Fields of papers citing papers by Selvi Durmuş

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Selvi Durmuş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Selvi Durmuş. The network helps show where Selvi Durmuş may publish in the future.

Co-authorship network of co-authors of Selvi Durmuş

This figure shows the co-authorship network connecting the top 25 collaborators of Selvi Durmuş. A scholar is included among the top collaborators of Selvi Durmuş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Selvi Durmuş. Selvi Durmuş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ABC transporters Mdr1a/1b, Bcrp1, Mrp2 and Mrp3 determine the sensitivity to PhIP/DSS-induced colon carcinogenesis and inflammation 2019 ·Archives of Toxicology ·Selvi Durmuş, Martin van der Valk, (unknown), Ji-Ying Song, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel	10
2	Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer 2018 ·Oncogene ·Özge Saatci, Simone Borgoni, Özge Akbulut, Selvi Durmuş, Umar Raza, Erol Eyüpoğlu, Can Alkan, Aytekin Akyol, Özgür Kütük, Stefan Wiemann, Özgür Şahin	66
3	The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice 2016 ·Drug Resistance Updates ·Selvi Durmuş, Stéphanie van Hoppe, Alfred H. Schinkel	45
4	Cationic Pd(II)/Pt(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine: Synthesis, structures,DNA/BSA interactions, intracellular distribution, cytotoxic activity and induction of apoptosis 2015 ·Journal of Inorganic Biochemistry ·Ceyda İçsel, Veysel T. Yılmaz, Yunus Kaya, Selvi Durmuş, Mehmet Sarımahmut, Orhan Büyükgüngör, Engı̇n Ulukaya	42
5	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b 2015 ·Cancer Research ·Aksana Vasilyeva, Selvi Durmuş, Lie Li, Els Wagenaar, Shuiying Hu, Alice A. Gibson, John C. Panetta, Sridhar Mani, Alex Sparreboom, Sharyn D. Baker, Alfred H. Schinkel	59
6	Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition 2015 ·Advances in cancer research ·Selvi Durmuş, Jeroen J. M. A. Hendrikx, Alfred H. Schinkel	78
7	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) 2015 ·Pharmaceutical Research ·(unknown), Selvi Durmuş, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel	56
8	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice 2014 ·Clinical Cancer Research ·Seng Chuan Tang, Rolf W. Sparidans, (unknown), Tatsuki Fukami, Selvi Durmuş, Els Wagenaar, Tsuyoshi Yokoi, Bart J.M. van Vlijmen, Jos H. Beijnen, Alfred H. Schinkel	31
9	In vivodisposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters 2014 ·International Journal of Cancer ·Selvi Durmuş, (unknown), Levi C.M. Buil, Els Wagenaar, Olaf van Tellingen, Alfred H. Schinkel	45
10	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) 2014 ·Pharmaceutical Research ·Selvi Durmuş, Rolf W. Sparidans, Anita van Esch, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel	85
11	Liquid chromatography–tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma 2014 ·Biomedical Chromatography ·Dino Luethi, Selvi Durmuş, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen, Rolf W. Sparidans	23
12	Liquid chromatography–tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma 2013 ·Journal of Chromatography B ·Dino Luethi, Selvi Durmuş, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen, Rolf W. Sparidans	12
13	Liquid chromatography–tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma 2013 ·Journal of Pharmaceutical and Biomedical Analysis ·Rolf W. Sparidans, Selvi Durmuş, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen	16
14	Liquid chromatography–tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma 2013 ·Journal of Chromatography B ·Rolf W. Sparidans, Selvi Durmuş, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen	13
15	P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387 2013 ·Pharmacological Research ·Selvi Durmuş, Ning Xu, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel	32
16	Oral Availability and Brain Penetration of the B-RAF ^V600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar 2012 ·Molecular Pharmaceutics ·Selvi Durmuş, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, Alfred H. Schinkel	102
17	Liquid chromatography–tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma 2012 ·Journal of Chromatography B ·Rolf W. Sparidans, Selvi Durmuş, Ning Xu, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen	9
18	Liquid chromatography–tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma 2012 ·Journal of Chromatography B ·Rolf W. Sparidans, Selvi Durmuş, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen	14
19	Liquid chromatography–tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+-glucuronide in plasma 2012 ·Journal of Chromatography B ·Rolf W. Sparidans, Selvi Durmuş, Ning Xu, Alfred H. Schinkel, Jan H.M. Schellens, Jos H. Beijnen	2
20	MicroRNAs, macrocontrol: Regulation of miRNA processing 2010 ·RNA ·Izabella Ślęzak-Prochazka, Selvi Durmuş, Bart‐Jan Kroesen, Anke van den Berg	221

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact